GSK'S consumer healthcare brands, Panadol, Voltaren and Centrum, are being rolled into a new company, Haleon, ahead of a demerger later this year.
The Haleon brand will be deployed in more than 100 markets around the globe, as a standalone company.
The new company is the result of a series of investments and strategic changes to GSK's consumer health business over the last eight years, including the integration of product portfolios from Novartis and Pfizer.
GSK CEO, Emma Walmsley, said that "Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health".
Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders," she said.
"Haleon will have a world-class portfolio of category-leading global brands, including Panadol, Voltaren, Sensodyne and Centrum.
"Its brands are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities."
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Feb 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Feb 22
